Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer

Published version of a preprint

Abstract

Purpose: Cancer-initiating cells (C-IC) have been described in multiple cancer types, including colorectal cancer. C-ICs are defined by their capacity to self-renew, thereby driving tumor growth. C-ICs were initially thought to be static entities; however, recent studies have determined these cells to be dynamic and influenced by microenvironmental cues such as hypoxia. If hypoxia drives the formation of C-ICs, then therapeutic targeting of hypoxia could represent a novel means to target C-ICs. Experimental Design: Patient-derived colorectal cancer xenografts were treated with evofosfamide, a hypoxia-activated prodrug (HAP), in combination with 5-fluorouracil (5-FU) or chemoradiotherapy (5-FU and radiation; CRT). Treatment groups included both concurrent and sequential dosing regimens. Effects on the colorectal cancer-initiating cell (CC-IC) fraction were assessed by serial passage in vivo limiting dilution assays. FAZA-PET imaging was utilized as a noninvasive method to assess intratumoral hypoxia. Results: Hypoxia was sufficient to drive the formation of CC-ICs and colorectal cancer cells surviving conventional therapy were more hypoxic and C-IC-like. Using a novel approach to combination therapy, we show that sequential treatment with 5-FU or CRT followed by evofosfamide not only inhibits tumor growth of xenografts compared with 5-FU or CRT alone, but also significantly decreases the CC-IC fraction. Furthermore, noninvasive FAZA-PET hypoxia imaging was predictive of a tumor's response to evofosfamide. Conclusions: Our data demonstrate a novel means to target the CC-IC fraction by adding a HAP sequentially after conventional adjuvant therapy, as well as the use of FAZA-PET as a biomarker for hypoxia to identify tumors that will benefit most from this approach. Clin Cancer Res; 24(9); 2116–27. ©2018 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1715

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 27

Metadata

Authors
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., Vines, D. C., Haibe-Kains, B., Wouters, B. G., Metser, U., Jaffray, D. A., Smith, M., & O'Brien, C. A.
Affiliations
  • University Health Network (CA)
  • 4Structural Genomics Consortium, Toronto, Ontario, Canada.
  • 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Institute of Cancer Research (GB)
Venue
Clinical Cancer Research
Published
2018-04-30
Volume
24
Issue
9
Pages
2116-2127
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2791469985
Cited by
22
References
51
Citations by year
2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 1 · 2019: 3 · 2018: 1
FWCI
0.90
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
Gouvernement du Canada | CIHR | Institute of Cancer Research (ICR)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
evofosfamide, hypoxia-activated prodrug, colorectal cancer, cancer stem cells, tumor hypoxia, 5-fluorouracil, chemoradiotherapy, sequential therapy, adjuvant therapy, limiting dilution assay, hypoxia markers, patient-derived xenografts
MeSH terms
Animals, Hypoxia, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Male, Nitroimidazoles, Phenotype, Phosphoramide Mustards, Prodrugs, Neoplastic Stem Cells, Colorectal Neoplasms, Biomarkers, Cell Hypoxia, Caspases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Positron-Emission Tomography, Mice, Standard of Care, Chemoradiotherapy, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1715
The paper
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., Vines, D. C., Haibe-Kains, B., Wouters, B. G., Metser, U., Jaffray, D. A., Smith, M., & O'Brien, C. A. (2018). Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.